Tag: Met inhibitor

Over the past decade, the landscape for non-small cell lung cancer (NSCLC) treatment has transformed with the rise of targeted therapies based on specific molecular alterations. A key player in this evolution is the medication tepotinib, which is indeed a potent and highly selective MET inhibitor.

Affecting 3–4% of non-small cell lung cancer (NSCLC) patients, MET exon 14 skipping alterations are a specific therapeutic target. Understanding **what is the mechanism of action of tepotinib** is key to appreciating how this targeted therapy addresses such mutations by selectively inhibiting the MET tyrosine kinase receptor. This dual-action inhibitor not only controls tumor growth by blocking the MET signaling pathway but also combats multidrug resistance.